Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Role of economic models in randomized clinical trials.
Hlatky
M A
MA
Departments of Health Research and Policy and Medicine, Stanford University School of Medicine, Stanford, CA, USA.
D002317:Cardiovascular Agents / Q000191:economics* / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000191:economics; D003362:Cost-Benefit Analysis / Q000379:methods*; D019049:Developed Countries; D017850:Economics, Pharmaceutical; D006801:Humans; D018803:Models, Economic; D016032:Randomized Controlled Trials as Topic / Q000191:economics*
D002317:Cardiovascular Agents